CTEC:LSE-ConvaTec Group PLC (GBX)

COMMON STOCK | Medical Instruments & Supplies | LSE

Last Closing Price

GBX 225.00

Change

-1.40 (-0.62)%

Market Cap

GBX 4.59B

Volume

1.86M

Avg Analyst Target

GBX 237.50 (+5.56%)

Avg User Target

GBX
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


CTEC Stock Forecast & Price:
Based on the ConvaTec Group PLC stock forecasts from 4 analysts, the average analyst target price for ConvaTec Group PLC is GBX 237.50 over the next 12 months. ConvaTec Group PLC’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of ConvaTec Group PLC is Neutral, which is based on 8 positive signals and 9 negative signals. At the last closing, ConvaTec Group PLC’s stock price was GBX 225.00. ConvaTec Group PLC’s stock price has changed by -2.09% over the past week, +5.44% over the past month and -8.01% over the last year.

About ConvaTec Group PLC (CTEC:LSE)

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-05 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AMS:LSE Advanced Medical Solutions Gro..

+0.50 (+0.17%)

GBX0.64B 3,687.50 18.49
TSTL:LSE Tristel

N/A

GBX0.17B 7,050.00 28.20
BVC:LSE Batm Advanced Communications L..

-1.48 (-4.32%)

GBX0.15B 1,146.67 3.51
ODX:LSE Omega Diagnostics Group Plc

-0.05 (-1.52%)

GBX7.37M 16.43 -1.64

ETFs Containing CTEC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.49% 100% A+ 93% A
Dividend Return 0.02% 100% A+ 47% F
Total Return 16.51% 100% A+ 93% A
Trailing 12 Months  
Capital Gain -8.76% 80% B- 60% D-
Dividend Return 0.02% 100% A+ 32% F
Total Return -8.74% 80% B- 60% D-
Trailing 5 Years  
Capital Gain -25.82% 40% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.82% 40% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 1.04% 40% F 31% F
Dividend Return 1.57% 100% A+ 60% D-
Total Return 2.61% 40% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 25.72% 80% B- 47% F
Risk Adjusted Return 10.13% 40% F 33% F
Market Capitalization 4.59B 100% A+ 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 4,500.00 40% F 4% F
Price/Book Ratio 3.40 40% F 18% F
Price / Cash Flow Ratio 15.02 80% B- 28% F
EV/EBITDA 13.78 60% D- 21% F
Management Effectiveness  
Return on Equity 6.99% 40% F 38% F
Return on Invested Capital 5.51% 40% F 59% F
Return on Assets 3.89% 60% D- 57% F
Debt to Equity Ratio 70.79% 33% F 29% F
Technical Ratios  
Dividend Yield 1.96% 75% C 41% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.71 40% F 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector